Viewing nowCombinationJanudam M Tablet 50/500 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewoong Bio Co., Ltd.

MFDS item code 202200205 · Approved 2022.01.12 · Insurance code 694004010
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used to improve blood sugar control in patients with Type 2 diabetes. It can be given alone as initial treatment and is provided as an alternative therapy when blood sugar control is difficult with monotherapy of metformin or sitagliptin. It can also be combined with multiple medications such as metformin, sulfonylureas, thiazolidinediones, and insulin to assist in achieving more effective blood sugar control. Depending on the patient's condition, various combination therapies can be used to aid in blood sugar management. This medication complements dietary control and exercise therapy to effectively improve blood sugar.
The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medication should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this medication is 1 tablet of 50/500 mg twice daily. The dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Patients Who Must Not Take This Medication). 2. Patients receiving metformin: - The recommended initial dose of this medication for patients who do not achieve adequate glycemic control with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching to this medication from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When this medication is used with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medication. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medication because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Take This Medication).
This medication may cause severe allergic reactions; therefore, if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur, immediately discontinue use and consult a doctor. During use, a serious inflammation of the pancreas called pancreatitis may occur, so if sudden abdominal pain, nausea, vomiting, fever, etc. are present, visit a hospital immediately. In patients with severe renal impairment or conditions such as severe infections, dehydration, heart failure, or acute myocardial infarction, taking this medication may be dangerous, therefore it should not be administered. Before undergoing examinations using radiopaque agents, this medication should be temporarily discontinued; after confirming normal kidney function afterward, it can be resumed. It is safer for women who are pregnant or possibly pregnant, as well as lactating women, to refrain from taking this medication. This medication can cause hypoglycemia, so blood sugar levels must be carefully monitored, especially when taken with insulin or other hypoglycemic agents. Rare but severe metabolic abnormalities known as lactic acidosis may occur, so if symptoms such as muscle pain, fatigue, shortness of breath, or abdominal pain appear, immediately notify healthcare personnel and discontinue use. Alcohol consumption may increase the risk of side effects from this medication, so avoiding drinking during use is advised. Elderly patients or those with reduced kidney function should have their dosage adjusted and undergo regular kidney function tests. It is important to regularly undergo blood tests and kidney function tests while taking this medication to detect and manage adverse reactions early. For patients scheduled for surgery, discontinue use 48 hours prior to the procedure, and resume only after confirming normal kidney function post-surgery. If severe joint pain or blistering on the skin occurs during the course of this medication, consult a doctor immediately, and discontinuation may be necessary. If taking other medications that may interact with this drug, inform your doctor or pharmacist, as interactions could alter effectiveness, so caution is warranted.
Not everyone experiences these, and they can vary from person to person.
Store this medication in an airtight container that is well-ventilated, and it is advisable to keep it at a temperature between 1 and 30 degrees Celsius. This storage will help maintain the efficacy of the medication for a longer period.
Light pink oval film-coated tablet
30 tablets per box [(10 tablets/PTP x 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewoong Bio Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.